Business Description
PsiOxus Therapeutics is a developer of novel therapeutics for solid tumours through its proprietary targeted oncolytic virus and tumour-specific immuno-gene therapy platform (T-SIGn).
Rationale for Investment
To be a world-leading cancer gene therapy company, developing an internal programme and entering into commercial partnerships to advance a oncolytic virus pipeline.